These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

629 related items for PubMed ID: 9030236

  • 1. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
    Ekimoto H.
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
    [Abstract] [Full Text] [Related]

  • 2. [Development of anti-cancer drugs under new renewed GCP--from the viewpoint of drug development company developer].
    Ueno T, Kobayashi T, Inoue K, Yanagi Y, Yamada Y.
    Gan To Kagaku Ryoho; 1998 Apr; 25(5):663-70. PubMed ID: 9571963
    [Abstract] [Full Text] [Related]

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 4. Anticancer Drug Development: The Way Forward.
    Connors T.
    Oncologist; 1996 Dec; 1(3):180-181. PubMed ID: 10387985
    [Abstract] [Full Text] [Related]

  • 5. The NCI All Ireland Cancer Conference.
    Johnston PG, Daly PA, Liu E.
    Oncologist; 1999 Dec; 4(4):275-277. PubMed ID: 10545862
    [Abstract] [Full Text] [Related]

  • 6. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M, Bertram D.
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [Abstract] [Full Text] [Related]

  • 7. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J.
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [Abstract] [Full Text] [Related]

  • 8. Industry perspectives on ICH guidelines.
    Rockhold FW.
    Stat Med; 2002 Oct 15; 21(19):2949-57. PubMed ID: 12325111
    [Abstract] [Full Text] [Related]

  • 9. [Development and perspectives of community DOTS].
    Narita T, Kobayashi N.
    Kekkaku; 2009 Apr 15; 84(4):187-201. PubMed ID: 19425394
    [Abstract] [Full Text] [Related]

  • 10. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology.
    J Clin Oncol; 2003 Jun 15; 21(12):2397-406. PubMed ID: 12692171
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Implementation of new Japanese GCP and the quality of clinical trials--from the standpoint of the pharmaceutical industry].
    Ebi O.
    Gan To Kagaku Ryoho; 1997 Oct 15; 24(13):1883-91. PubMed ID: 9350232
    [Abstract] [Full Text] [Related]

  • 18. [Tuberculosis and its control--lessons from the past and future prospect].
    Shimao T.
    Kekkaku; 2005 Jun 15; 80(6):481-9. PubMed ID: 16130906
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Globalization of clinical trials].
    Akaza H, Fukuoka M, Ohtsu A, Usami M, Ikeda T, Aiba K, Isonishi S, Ohashi Y, Saijo N, Sone S, Tsukagoshi S, Tsuruo T, Kato M, Mikami O, Dong RP, von Euler M, Blackledge G, Stribling D.
    Gan To Kagaku Ryoho; 2003 Apr 15; 30(4):555-65. PubMed ID: 12722692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.